Literature DB >> 12149159

Phytotherapy for benign prostatic hyperplasia.

Glenn S Gerber1.   

Abstract

Phytotherapy has become a more popular treatment option among American men with benign prostatic hyperplasia (BPH). The most popular herbal agent is saw palmetto (Serenoa repens), which is derived from the berry of the American dwarf palm tree. Pygeum africanum and beta-sitosterol are also used by many patients with BPH, either alone or in combination with saw palmetto. A significant limiting factor to our understanding of the use and effectiveness of phytotherapy is the lack of standardization of these products. Despite this lack of standardization and the variation in results that may be seen with herbal products, there is growing evidence from well-conducted clinical trials that phytotherapeutic agents may lead to subjective and objective symptom improvement beyond a placebo effect in men with BPH. In addition, histologic evidence has been presented demonstrating that saw palmetto causes atrophy and epithelial contraction within the prostate gland. Overall, it is likely that herbal therapy will continue to be used by a growing number of Americans to treat a variety of ailments. Physicians should attempt to remain open-minded regarding alternative approaches and educate themselves so that they may counsel patients in an informed and credible fashion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149159     DOI: 10.1007/s11934-002-0050-3

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  29 in total

1.  Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.

Authors:  S Dutkiewicz
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

2.  Functional evaluation of Tadenan on micturition and experimental prostate growth induced with exogenous dihydrotestosterone.

Authors:  M S Choo; F Bellamy; C E Constantinou
Journal:  Urology       Date:  2000-02       Impact factor: 2.649

Review 3.  Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

4.  Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.

Authors:  J C Carraro; J P Raynaud; G Koch; G D Chisholm; F Di Silverio; P Teillac; F C Da Silva; J Cauquil; D K Chopin; F C Hamdy; M Hanus; D Hauri; A Kalinteris; J Marencak; A Perier; P Perrin
Journal:  Prostate       Date:  1996-10       Impact factor: 4.104

5.  [Controlled study of the effects of Pygeum africanum extract on the functional symptoms of prostatic adenoma].

Authors:  B Dufour; C Choquenet; M Revol; G Faure; R Jorest
Journal:  Ann Urol (Paris)       Date:  1984-05

6.  Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers.

Authors:  G Strauch; P Perles; G Vergult; M Gabriel; B Gibelin; S Cummings; W Malbecq; M P Malice
Journal:  Eur Urol       Date:  1994       Impact factor: 20.096

7.  Treatment of benign prostatic hyperplasia with phytosterols.

Authors:  B E Carbin; B Larsson; O Lindahl
Journal:  Br J Urol       Date:  1990-12

8.  Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.

Authors:  R R Berges; J Windeler; H J Trampisch; T Senge
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

9.  Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review.

Authors:  T J Wilt; A Ishani; G Stark; R MacDonald; J Lau; C Mulrow
Journal:  JAMA       Date:  1998-11-11       Impact factor: 56.272

10.  Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts.

Authors:  C Sultan; A Terraza; C Devillier; E Carilla; M Briley; C Loire; B Descomps
Journal:  J Steroid Biochem       Date:  1984-01       Impact factor: 4.292

View more
  6 in total

1.  Towards the prevention and management of prostatic diseases in Nigeria: a framework.

Authors:  Chukwunonso Ecc Ejike
Journal:  Malays J Med Sci       Date:  2011-07

2.  Androgen deprivation induces rapid involution and recovery of human prostate vasculature.

Authors:  Alejandro Godoy; Viviana P Montecinos; Danny R Gray; Paula Sotomayor; Jeffrey M Yau; R Robert Vethanayagam; Swaroop Singh; James L Mohler; Gary J Smith
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-08-10       Impact factor: 4.310

3.  Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo.

Authors:  Nader S Shenouda; Mary S Sakla; Leslie G Newton; Cynthia Besch-Williford; Norman M Greenberg; Ruth S MacDonald; Dennis B Lubahn
Journal:  Endocrine       Date:  2007-02       Impact factor: 3.633

Review 4.  Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction.

Authors:  Serap Gur; Philip J Kadowitz; Wayne J G Hellstrom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Antiproliferative and Antioxidant Effects of Withania coagulans Extract on Benign Prostatic Hyperplasia in Rats.

Authors:  Maryam Sarbishegi; Mohaddeseh Khani; Saeedeh Salimi; Mohharam Valizadeh; Fereydoon Sargolzaei Aval
Journal:  Nephrourol Mon       Date:  2016-01-09

6.  Action Mechanism of Ginkgo biloba Leaf Extract Intervened by Exercise Therapy in Treatment of Benign Prostate Hyperplasia.

Authors:  Chiung-Chi Peng; Jia-Hong Liu; Chi-Huang Chang; Jin-Yuan Chung; Kuan-Chou Chen; Kuang-Yu Chou; Robert Y Peng
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-16       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.